AdaptHealth Corp. (NASDAQ:AHCO) Expected to Announce Quarterly Sales of $643.13 Million

Equities analysts expect that AdaptHealth Corp. (NASDAQ:AHCOGet Rating) will post sales of $643.13 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for AdaptHealth’s earnings. The lowest sales estimate is $634.80 million and the highest is $653.00 million. AdaptHealth reported sales of $482.12 million in the same quarter last year, which indicates a positive year-over-year growth rate of 33.4%. The business is scheduled to issue its next earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that AdaptHealth will report full year sales of $2.92 billion for the current financial year, with estimates ranging from $2.87 billion to $2.95 billion. For the next financial year, analysts anticipate that the business will post sales of $3.25 billion, with estimates ranging from $3.14 billion to $3.35 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover AdaptHealth.

AdaptHealth (NASDAQ:AHCOGet Rating) last posted its earnings results on Thursday, February 24th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.25). The business had revenue of $702.11 million during the quarter, compared to the consensus estimate of $693.15 million. AdaptHealth had a return on equity of 7.97% and a net margin of 6.36%.

AHCO has been the subject of several recent research reports. SVB Leerink decreased their target price on shares of AdaptHealth from $32.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, March 2nd. Truist Financial decreased their target price on shares of AdaptHealth from $30.00 to $20.00 in a research report on Friday, February 25th. Canaccord Genuity Group reduced their price objective on shares of AdaptHealth from $44.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, February 25th. Royal Bank of Canada reduced their price objective on shares of AdaptHealth from $31.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, March 8th. Finally, Zacks Investment Research cut shares of AdaptHealth from a “hold” rating to a “strong sell” rating in a research note on Wednesday, April 27th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.14.

In other AdaptHealth news, CEO Stephen P. Griggs acquired 32,342 shares of the company’s stock in a transaction dated Thursday, March 3rd. The stock was bought at an average price of $15.44 per share, for a total transaction of $499,360.48. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Skyknight Capital Fund Ii, L.P acquired 17,486 shares of the company’s stock in a transaction dated Friday, March 11th. The stock was acquired at an average price of $15.50 per share, with a total value of $271,033.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 88,180 shares of company stock valued at $1,351,923. Corporate insiders own 17.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Covestor Ltd acquired a new position in shares of AdaptHealth in the 4th quarter valued at $35,000. Nisa Investment Advisors LLC raised its stake in shares of AdaptHealth by 96.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,710 shares of the company’s stock valued at $27,000 after buying an additional 840 shares in the last quarter. US Bancorp DE raised its stake in shares of AdaptHealth by 142.4% in the 3rd quarter. US Bancorp DE now owns 1,939 shares of the company’s stock valued at $46,000 after buying an additional 1,139 shares in the last quarter. Advisor Group Holdings Inc. raised its stake in shares of AdaptHealth by 306.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 3,000 shares of the company’s stock valued at $73,000 after buying an additional 2,262 shares in the last quarter. Finally, Islay Capital Management LLC acquired a new position in shares of AdaptHealth in the 4th quarter valued at $124,000. Institutional investors own 83.68% of the company’s stock.

AHCO stock opened at $11.43 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.34 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of 29.31, a P/E/G ratio of 0.23 and a beta of 0.47. AdaptHealth has a 12 month low of $11.40 and a 12 month high of $30.33. The firm has a 50 day moving average of $15.42 and a two-hundred day moving average of $19.19.

About AdaptHealth (Get Rating)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

Further Reading

Get a free copy of the Zacks research report on AdaptHealth (AHCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AdaptHealth (NASDAQ:AHCO)

Receive News & Ratings for AdaptHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdaptHealth and related companies with MarketBeat.com's FREE daily email newsletter.